Home World News FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A... World News FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 952 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 6 Things That Helped Me Think Positively During Cancer: A Patient... August 16, 2022 Spirituality Resources December 9, 2020 Survey Shows Oncologists Underestimate How Many Cancer Patients Use Alternative Therapies June 16, 2021 Load more HOT NEWS What to Know About Peer-Reviewed Cancer Information and Its Role in... Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining Presence of Tumour and Higher Levels of LAG3-positive T-cells in the...
